Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Shares in SK Corp. took a six percent hike Wednesday after announcing plans to list its subsidiary SK Biopharmaceuticals to raise 959.3 billion won.
It will be South Korea's biggest stock market debut since May 2017, when mobile gaming firm Netmarble raised 2.7 trillion won.
SK Biopharmaceuticals' anti-epilepsy drug, Cenobamate, began to sell in the US this month after the US Food and Drug Administration approved it in November.
The company will sell about 25 percent of its shares, with the final pricing of the share offering expected to on June 18.
Mirae Asset Daewoo Securities analyst Chung Dae-ro projects the company's market value to reach five trillion won.
After the Covid-19 pandemic pushed South Korean companies to postpone listing plans, many smaller companies in the country are now preparing to go public as the health situation improves.
An investment banker noted that the mood has changed since April as the stock market recovers.
South Korea's benchmark Kospi stock index has increased by more than a third since March.
Other companies expected to go public this year include Big Hit, the music label behind South Korean boy band BTS, which is eyeing to raise nearly around 1.226 trillion won.
There's also Hyundai Card, the credit card unit of Hyundai Motor Group, which is preparing a 2.45 trillion won listing.
